Compass Therapeutics, Inc. (CMPX) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Mar-31-20	Dec-31-19	Mar-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	10-K	10-K	S-1/A
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	11.7	10.9	27.8	0.0	11.6	0.0	11.2
General and administrative	11.7	10.9		0.0	11.6	0.0	11.2
Research and development	30.0	20.3	14.9		22.4		27.1
Other operating expenses			-42.7
EBITDA [+]	-40.9	-30.7	2.4		-31.9		-36.4
EBITDA growth	33.1%	-1377.0%	-107.5%	-2.0%	-12.3%
Depreciation and amortization	0.8	0.6	2.4		2.1		1.9
EBIT [+]	-41.7	-31.3	0.0	0.0	-34.1	0.0	-38.3
EBIT growth	33.2%		-100.0%	-2.0%	-11.1%
Non-recurring items [+]		50.6
In-process research & development		50.6
Interest income, net [+]	2.4	0.0	0.1	0.0	-0.5	0.0	-0.1
Interest expense		0.4	0.9	0.0	1.2	0.0	0.8
Interest income	2.4	0.0	0.1		0.7		0.7
Other income (expense), net [+]	0.1	0.0	-28.6		-0.1		0.2
Gain (loss) on derivative instruments							-0.1
Gain (loss) on foreign currency transactions							0.0
Other	2.4	-0.3			0.6
Pre-tax income	-39.2	-82.2	-29.5	0.0	-34.7	0.0	-38.2
Income taxes	0.0	0.0	0.0	0.0	0.1	0.0	0.1
Tax rate	0.0%	0.0%		0.0%		0.0%
Net income	-39.2	-82.2	-29.5	0.0	-34.7	0.0	-38.3

Basic EPS [+]	($0.37)	($1.31)	($0.96)	($0.01)	($5.19)	($0.01)
Growth	-71.5%	36.4%	-81.5%	4.0%
Diluted EPS [+]	($0.37)	($1.31)	($0.96)	($0.01)	($5.19)	($0.01)
Growth	-71.5%	36.4%	-81.5%	4.0%

Shares outstanding (basic) [+]	105.2	62.9	30.8	5.0	6.7	5.0
Growth	67.3%	104.3%	360.0%	0.0%
Shares outstanding (diluted) [+]	105.2	62.9	30.8	5.0	6.7	5.0
Growth	67.3%	104.3%	360.0%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.